GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cotinga Pharmaceuticals Inc (OTCPK:COTQF) » Definitions » Gross Margin %

Cotinga Pharmaceuticals (Cotinga Pharmaceuticals) Gross Margin % : 0.00% (As of Jan. 2020)


View and export this data going back to 2007. Start your Free Trial

What is Cotinga Pharmaceuticals Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Cotinga Pharmaceuticals's Gross Profit for the three months ended in Jan. 2020 was $0.00 Mil. Cotinga Pharmaceuticals's Revenue for the three months ended in Jan. 2020 was $0.00 Mil. Therefore, Cotinga Pharmaceuticals's Gross Margin % for the quarter that ended in Jan. 2020 was 0.00%. If there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.


The historical rank and industry rank for Cotinga Pharmaceuticals's Gross Margin % or its related term are showing as below:


COTQF's Gross Margin % is not ranked *
in the Biotechnology industry.
Industry Median: 60.91
* Ranked among companies with meaningful Gross Margin % only.

Cotinga Pharmaceuticals had a gross margin of N/A% for the quarter that ended in Jan. 2020 => No sustainable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Cotinga Pharmaceuticals was 0.00% per year.


Cotinga Pharmaceuticals Gross Margin % Historical Data

The historical data trend for Cotinga Pharmaceuticals's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cotinga Pharmaceuticals Gross Margin % Chart

Cotinga Pharmaceuticals Annual Data
Trend Apr10 Apr11 Apr12 Apr13 Apr14 Apr15 Apr16 Apr17 Apr18 Apr19
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Cotinga Pharmaceuticals Quarterly Data
Apr15 Jul15 Oct15 Jan16 Apr16 Jul16 Oct16 Jan17 Apr17 Jul17 Oct17 Jan18 Apr18 Jul18 Oct18 Jan19 Apr19 Jul19 Oct19 Jan20
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Cotinga Pharmaceuticals's Gross Margin %

For the Biotechnology subindustry, Cotinga Pharmaceuticals's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cotinga Pharmaceuticals's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cotinga Pharmaceuticals's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Cotinga Pharmaceuticals's Gross Margin % falls into.



Cotinga Pharmaceuticals Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

Cotinga Pharmaceuticals's Gross Margin for the fiscal year that ended in Apr. 2019 is calculated as

Gross Margin % (A: Apr. 2019 )=Gross Profit (A: Apr. 2019 ) / Revenue (A: Apr. 2019 )
=0 / 0
=(Revenue - Cost of Goods Sold) / Revenue
=(0 - 0) / 0
=N/A %

Cotinga Pharmaceuticals's Gross Margin for the quarter that ended in Jan. 2020 is calculated as


Gross Margin % (Q: Jan. 2020 )=Gross Profit (Q: Jan. 2020 ) / Revenue (Q: Jan. 2020 )
=0 / 0
=(Revenue - Cost of Goods Sold) / Revenue
=(0 - 0) / 0
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Cotinga Pharmaceuticals  (OTCPK:COTQF) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Cotinga Pharmaceuticals had a gross margin of N/A% for the quarter that ended in Jan. 2020 => No sustainable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Cotinga Pharmaceuticals Gross Margin % Related Terms

Thank you for viewing the detailed overview of Cotinga Pharmaceuticals's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Cotinga Pharmaceuticals (Cotinga Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
82 Richmond Street East, The Canadian Venture Building, Toronto, ON, CAN, M5C1P1
Cotinga Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's lead clinical candidate, COTI-2, is an oral small molecule targeting p53, a tumor suppressor gene that is mutated in over 50% of all cancers, and the company's second clinical candidate, COTI-219, is a novel oral small molecule compound targeting the mutant forms of KRAS with such mutations occurring in up to 30% of all cancers.

Cotinga Pharmaceuticals (Cotinga Pharmaceuticals) Headlines

From GuruFocus

Cotinga Pharmacueticals Announces Closing of Unit Offering

By GlobeNewswire GlobeNewswire 05-22-2019